Theravance Biopharma (NASDAQ:TBPH) Trading 4.6% Higher After Analyst Upgrade

Key Points

• Theravance Biopharma's shares rose 4.6% to $14.33, with trading volume increasing 8% compared to the average, showing strong market interest.
• Analysts have upgraded the stock multiple times, with Zacks Research and Wall Street Zen both raising their ratings to "strong-buy" and setting a consensus price target of $23.00.
• Insider activity indicates confidence in the company, as 6.90% of the stock is owned by insiders, while institutional investors hold 99.10% of the shares.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) traded up 4.6% during trading on Friday after B. Riley upgraded the stock to a strong-buy rating. The stock traded as high as $14.25 and last traded at $14.33. 313,270 shares were traded during trading, an increase of 8% from the average session volume of 289,849 shares. The stock had previously closed at $13.70.

TBPH has been the topic of several other reports. Zacks Research raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Friday, August 15th. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 16th. BTIG Research increased their price target on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a report on Friday, June 27th. Finally, Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target on the stock in a report on Tuesday, June 17th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $23.00.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of Theravance Biopharma stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00. Following the transaction, the senior vice president directly owned 326,918 shares of the company's stock, valued at approximately $3,723,596.02. This trade represents a 2.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 6.90% of the company's stock.

Institutional Trading of Theravance Biopharma

Large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its holdings in shares of Theravance Biopharma by 1,201.8% during the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 3,281 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock valued at $55,000 after acquiring an additional 781 shares during the period. AQR Capital Management LLC bought a new position in Theravance Biopharma during the 1st quarter valued at about $101,000. R Squared Ltd lifted its stake in Theravance Biopharma by 636.6% during the 1st quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock valued at $112,000 after acquiring an additional 10,822 shares during the period. Finally, Creative Planning bought a new position in shares of Theravance Biopharma in the 2nd quarter worth approximately $139,000. Institutional investors own 99.10% of the company's stock.

Theravance Biopharma Trading Up 1.1%

The company's 50 day moving average price is $12.51 and its two-hundred day moving average price is $10.67. The stock has a market cap of $706.05 million, a P/E ratio of 58.68 and a beta of 0.05.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.